RxDoctor Payments Data

Anna Watson

Family · Monroe, LANPI 1154955755

Payments from drug & device makers

$1,621in general payments, 2019–2025

Across 81 payments — averaging $20.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$628
  • Endo Pharmaceuticals Inc.$332
  • Urovant Sciences Inc$181
  • Amgen$90
  • Johnson & Johnson$63
  • C. R. Bard, Inc. & Subsidiaries$58
  • plus $269 from 11 others

What the payments were for

  • Food & beverage$1,33682%
  • Education$28518%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,621 in reported general payments places this provider in the 70th percentile of 3,610 family providers in Louisiana.

See all family providers in Louisiana

Medicare billing

Part B allowed, 2024
$124,355
Medicare patients
573
Services billed
3,019

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron213$99,601
GemtesaVibegron44$20,106
Mirabegron ErMirabegron31$12,008
Estradiol120$8,737
Finasteride298$4,162
Tamsulosin Hcl311$3,507
NitrofurantoinNitrofurantoin Macrocrystal34$1,823
Methenamine Hippurate26$1,744
Oxybutynin Chloride ErOxybutynin Chloride104$1,490
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst62$1,450
Dutasteride14$725
Doxycycline Hyclate40$597
Ciprofloxacin Hcl95$397
Solifenacin Succinate14$360
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav18$175

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$628$99,601213 claims
Sumitomo Pharma America, Inc.Gemtesa$44$20,10644 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,610 family providers in Louisiana.

Other family in Monroe

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →